- Home
- DRUG vs DCTH Comparison
DRUG vs DCTH Comparison
Compare DRUG & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- DCTH
- Stock Information
- Founded
- DRUG 2019
- DCTH 1988
- Country
- DRUG United States
- DCTH United States
- Employees
- DRUG N/A
- DCTH N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- DCTH Medical/Dental Instruments
- Sector
- DRUG Health Care
- DCTH Health Care
- Exchange
- DRUG Nasdaq
- DCTH Nasdaq
- Market Cap
- DRUG 345.6M
- DCTH 388.3M
- IPO Year
- DRUG N/A
- DCTH N/A
- Fundamental
- Price
- DRUG $55.20
- DCTH $11.10
- Analyst Decision
- DRUG Strong Buy
- DCTH Strong Buy
- Analyst Count
- DRUG 9
- DCTH 4
- Target Price
- DRUG $81.67
- DCTH $24.50
- AVG Volume (30 Days)
- DRUG 90.8K
- DCTH 681.8K
- Earning Date
- DRUG 08-11-2025
- DCTH 11-07-2025
- Dividend Yield
- DRUG N/A
- DCTH N/A
- EPS Growth
- DRUG N/A
- DCTH N/A
- EPS
- DRUG N/A
- DCTH 0.06
- Revenue
- DRUG N/A
- DCTH $70,240,000.00
- Revenue This Year
- DRUG N/A
- DCTH $159.22
- Revenue Next Year
- DRUG N/A
- DCTH $42.78
- P/E Ratio
- DRUG N/A
- DCTH $197.68
- Revenue Growth
- DRUG N/A
- DCTH 491.35
- 52 Week Low
- DRUG $0.94
- DCTH $8.08
- 52 Week High
- DRUG $79.02
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- DRUG N/A
- DCTH 45.00
- Support Level
- DRUG N/A
- DCTH $10.43
- Resistance Level
- DRUG N/A
- DCTH $11.28
- Average True Range (ATR)
- DRUG 0.00
- DCTH 0.41
- MACD
- DRUG 0.00
- DCTH -0.02
- Stochastic Oscillator
- DRUG 0.00
- DCTH 23.22
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.